GeneralBullishBlockonomi · 3h ago6/10
📰
Moderna (MRNA) Stock Soars 13% on In Vivo CAR-T Breakthrough and Flu Vaccine Progress
Moderna's stock jumped 13% following two significant clinical developments: the unveiling of an in vivo CAR-T immunotherapy program targeting autoimmune diseases and a unanimous 9-0 FDA panel vote supporting its mRNA-based flu vaccine candidate. These milestones demonstrate the company's pipeline expansion beyond COVID-19 and validate its mRNA platform's versatility across therapeutic areas.